Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Nektar Therapeutics (NASDAQ: NKTR) was $46.84 for the day, up 6.45% from the previous closing price of $44.0. In other words, the price has increased by $6.45 from its previous closing price. On the day, 1.02 million shares were traded. NKTR stock price reached its highest trading level at $47.12 during the session, while it also had its lowest trading level at $43.6206.
Ratios:
Our analysis of NKTR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 1.96 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on November 26, 2025, initiated with a Buy rating and assigned the stock a target price of $102. On June 24, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $6.50 to $120. BTIG Research reiterated its Buy rating for the stock on June 24, 2025, while the target price for the stock was revised from $60 to $100.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 25 ’25 when Zalevsky Jonathan sold 1,157 shares for $54.28 per share. The transaction valued at 62,802 led to the insider holds 18,971 shares of the business.
Wilson Mark Andrew sold 630 shares of NKTR for $34,196 on Nov 25 ’25. The Chief Legal Officer now owns 21,585 shares after completing the transaction at $54.28 per share. On Nov 25 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 2,207 shares for $54.28 each. As a result, the insider received 119,796 and left with 54,245 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 952800000 and an Enterprise Value of 849671040. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.22 while its Price-to-Book (P/B) ratio in mrq is 10.82. Its current Enterprise Value per Revenue stands at 13.573 whereas that against EBITDA is -6.285.
Stock Price History:
The Beta on a monthly basis for NKTR is -0.89, which has changed by 2.4696295 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $66.92, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is -18.35%, while the 200-Day Moving Average is calculated to be 55.41%.
Shares Statistics:
NKTR traded an average of 892.34K shares per day over the past three months and 1276830 shares per day over the past ten days. A total of 20.34M shares are outstanding, with a floating share count of 20.07M. Insiders hold about 1.35% of the company’s shares, while institutions hold 70.48% stake in the company. Shares short for NKTR as of 1764288000 were 1818868 with a Short Ratio of 2.04, compared to 1761868800 on 1472153. Therefore, it implies a Short% of Shares Outstanding of 1818868 and a Short% of Float of 9.1000006.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$2.59, with high estimates of -$2.59 and low estimates of -$2.59.
Analysts are recommending an EPS of between -$8.32 and -$8.32 for the fiscal current year, implying an average EPS of -$8.32. EPS for the following year is -$11.86, with 2.0 analysts recommending between -$11.6 and -$12.12.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $15.81M to a low estimate of $6.9M. As of. The current estimate, Nektar Therapeutics’s year-ago sales were $29.18MFor the next quarter, 8 analysts are estimating revenue of $10.1M. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is $6M.
A total of 8 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $49.24M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $43.85M. In the same quarter a year ago, actual revenue was $98.43MBased on 8 analysts’ estimates, the company’s revenue will be $42.13M in the next fiscal year. The high estimate is $54.44M and the low estimate is $24M.
